{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T01:15:33Z","timestamp":1783559733936,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02152-0","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:25:43Z","timestamp":1777461943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Signal Transduction and Transcription Activator 1 in Pan-Cancer: Prognostic and Immunological Value"],"prefix":"10.1007","volume":"26","author":[{"given":"Ying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longguan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"2152_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"2152_CR2","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.Cd-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021;11:838\u201357. https:\/\/doi.org\/10.1158\/2159-8290.Cd-20-1680.","journal-title":"Cancer Discov"},{"key":"2152_CR3","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1186\/s12885-025-14246-1","volume":"25","author":"S Xu","year":"2025","unstructured":"Xu S, Chen Z, Chen X, Chu H, Huang X, Chen C, Liu H, Qu Y, Lu Z. Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses. BMC Cancer. 2025;25:1113. https:\/\/doi.org\/10.1186\/s12885-025-14246-1.","journal-title":"BMC Cancer"},{"key":"2152_CR4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1126\/science.8197455","volume":"264","author":"JE Darnell Jr","year":"1994","unstructured":"Darnell JE Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415\u201321. https:\/\/doi.org\/10.1126\/science.8197455.","journal-title":"Science"},{"key":"2152_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s0955-0674(00)00199-x","volume":"13","author":"JN Ihle","year":"2001","unstructured":"Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol. 2001;13:211\u20137. https:\/\/doi.org\/10.1016\/s0955-0674(00)00199-x.","journal-title":"Curr Opin Cell Biol"},{"key":"2152_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/jir.1997.17.121","volume":"17","author":"T Decker","year":"1997","unstructured":"Decker T, Kovarik P, Meinke A. GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res. 1997;17:121\u201334. https:\/\/doi.org\/10.1089\/jir.1997.17.121.","journal-title":"J Interferon Cytokine Res"},{"key":"2152_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","volume":"36","author":"GR Stark","year":"2012","unstructured":"Stark GR, Darnell JE. Jr. The JAK-STAT pathway at twenty. Immunity. 2012;36:503\u201314. https:\/\/doi.org\/10.1016\/j.immuni.2012.03.013.","journal-title":"Immunity"},{"key":"2152_CR8","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1038\/sj.onc.1203525","volume":"19","author":"CV Ramana","year":"2000","unstructured":"Ramana CV, Chatterjee-Kishore M, Nguyen H, Stark GR. Complex roles of Stat1 in regulating gene expression. Oncogene. 2000;19:2619\u201327. https:\/\/doi.org\/10.1038\/sj.onc.1203525.","journal-title":"Oncogene"},{"key":"2152_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4161\/jkst.20045","volume":"1","author":"L Avalle","year":"2012","unstructured":"Avalle L, Pensa S, Regis G, Novelli F, Poli V. STAT1 and STAT3 in tumorigenesis: A matter of balance. Jakstat. 2012;1:65\u201372. https:\/\/doi.org\/10.4161\/jkst.20045.","journal-title":"Jakstat"},{"key":"2152_CR10","doi-asserted-by":"publisher","first-page":"e1008824","DOI":"10.1080\/2162402x.2015.1008824","volume":"4","author":"R Bellucci","year":"2015","unstructured":"Bellucci R, Martin A, Bommarito D, Wang K, Hansen SH, Freeman GJ, Ritz J. Interferon-\u03b3-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology. 2015;4:e1008824. https:\/\/doi.org\/10.1080\/2162402x.2015.1008824.","journal-title":"Oncoimmunology"},{"key":"2152_CR11","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1158\/0008-5472.Can-05-3612","volume":"66","author":"TE Battle","year":"2006","unstructured":"Battle TE, Lynch RA, Frank DA. Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res. 2006;66:3649\u201357. https:\/\/doi.org\/10.1158\/0008-5472.Can-05-3612.","journal-title":"Cancer Res"},{"key":"2152_CR12","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1128\/mcb.00295-14","volume":"34","author":"C Semper","year":"2014","unstructured":"Semper C, Leitner NR, Lassnig C, Parrini M, Mahlak\u00f5iv T, Rammerstorfer M, Lorenz K, Rigler D, M\u00fcller S, Kolbe T, et al. STAT1\u03b2 is not dominant negative and is capable of contributing to gamma interferon-dependent innate immunity. Mol Cell Biol. 2014;34:2235\u201348. https:\/\/doi.org\/10.1128\/mcb.00295-14.","journal-title":"Mol Cell Biol"},{"key":"2152_CR13","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1016\/j.cell.2023.07.013","volume":"186","author":"Y Geffen","year":"2023","unstructured":"Geffen Y, Anand S, Akiyama Y, Yaron TM, Song Y, Johnson JL, Govindan A, Babur \u00d6, Li Y, Huntsman E, et al. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation. Cell. 2023;186:3945\u2013e39673926. https:\/\/doi.org\/10.1016\/j.cell.2023.07.013.","journal-title":"Cell"},{"key":"2152_CR14","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1093\/emboj\/19.15.4111","volume":"19","author":"M Chatterjee-Kishore","year":"2000","unstructured":"Chatterjee-Kishore M, Wright KL, Ting JP, Stark GR. How Stat1 mediates constitutive gene expression: a complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene. Embo j. 2000;19:4111\u201322. https:\/\/doi.org\/10.1093\/emboj\/19.15.4111.","journal-title":"Embo j"},{"key":"2152_CR15","doi-asserted-by":"publisher","first-page":"e2000117","DOI":"10.1371\/journal.pbio.2000117","volume":"14","author":"J Ho","year":"2016","unstructured":"Ho J, Pelzel C, Begitt A, Mee M, Elsheikha HM, Scott DJ, Vinkemeier U. STAT2 Is a Pervasive Cytokine Regulator due to Its Inhibition of STAT1 in Multiple Signaling Pathways. PLoS Biol. 2016;14:e2000117. https:\/\/doi.org\/10.1371\/journal.pbio.2000117.","journal-title":"PLoS Biol"},{"key":"2152_CR16","doi-asserted-by":"publisher","unstructured":"Shao S, Tsoi LC, Sarkar MK, Xing X, Xue K, Uppala R, Berthier CC, Zeng C, Patrick M, Billi AC, et al. IFN-\u03b3 enhances cell-mediated cytotoxicity against keratinocytes via JAK2\/STAT1 in lichen planus. Sci Transl Med. 2019;11. https:\/\/doi.org\/10.1126\/scitranslmed.aav7561.","DOI":"10.1126\/scitranslmed.aav7561"},{"key":"2152_CR17","doi-asserted-by":"publisher","first-page":"925537","DOI":"10.3389\/fonc.2022.925537","volume":"12","author":"M Zhou","year":"2022","unstructured":"Zhou M, Zhang P, Da M, Yang R, Ma Y, Zhao J, Ma T, Xia J, Shen G, Chen Y, et al. A pan-cancer analysis of the expression of STAT family genes in tumors and their relationship to the tumor microenvironment. Front Oncol. 2022;12:925537. https:\/\/doi.org\/10.3389\/fonc.2022.925537.","journal-title":"Front Oncol"},{"key":"2152_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13048-025-01780-6","volume":"18","author":"N Lan","year":"2025","unstructured":"Lan N, Li X, Qiao Y, Zhang S, Chen M, Yang X, Zou Y, Ren J, Pei M. STAT1\u03b2 modulates the tumor immune microenvironment to improve prognosis in ovarian cancer: a comprehensive study of transcriptional and protein expression differences. J Ovarian Res. 2025;18:192. https:\/\/doi.org\/10.1186\/s13048-025-01780-6.","journal-title":"J Ovarian Res"},{"key":"2152_CR19","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.3892\/ijo.2019.4779","volume":"54","author":"Y Nakayama","year":"2019","unstructured":"Nakayama Y, Mimura K, Tamaki T, Shiraishi K, Kua LF, Koh V, Ohmori M, Kimura A, Inoue S, Okayama H, et al. Phospho\u2013STAT1 expression as a potential biomarker for anti\u2013PD\u20131\/anti\u2013PD\u2013L1 immunotherapy for breast cancer. Int J Oncol. 2019;54:2030\u20138. https:\/\/doi.org\/10.3892\/ijo.2019.4779.","journal-title":"Int J Oncol"},{"key":"2152_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375:819\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1604958.","journal-title":"N Engl J Med"},{"key":"2152_CR21","doi-asserted-by":"publisher","first-page":"175883592091755","DOI":"10.1177\/1758835920917558","volume":"12","author":"J Zhang","year":"2020","unstructured":"Zhang J, Wang F, Liu F, Xu G. Predicting STAT1 as a prognostic marker in patients with solid cancer. Ther Adv Med Oncol. 2020;12:1758835920917558. https:\/\/doi.org\/10.1177\/1758835920917558.","journal-title":"Ther Adv Med Oncol"},{"key":"2152_CR22","doi-asserted-by":"publisher","first-page":"872","DOI":"10.18632\/aging.205426","volume":"16","author":"G Wang","year":"2024","unstructured":"Wang G, Li Y, Pan R, Yin X, Jia C, She Y, Huang L, Yang G, Chi H, Tian G. XRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis. Aging. 2024;16:872\u2013910. https:\/\/doi.org\/10.18632\/aging.205426.","journal-title":"Aging"},{"key":"2152_CR23","doi-asserted-by":"publisher","first-page":"101953","DOI":"10.1016\/j.tranon.2024.101953","volume":"44","author":"Y Song","year":"2024","unstructured":"Song Y, Guo J-F, Lan P-S, Wang M, Du Q-Y. Investigation of the pan-cancer property of FNDC1 and its molecular mechanism to promote lung adenocarcinoma metastasis. Translational Oncol. 2024;44:101953. https:\/\/doi.org\/10.1016\/j.tranon.2024.101953.","journal-title":"Translational Oncol"},{"key":"2152_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1042\/cs20180816","volume":"133","author":"C Liu","year":"2019","unstructured":"Liu C, Shi J, Li Q, Li Z, Lou C, Zhao Q, Zhu Y, Zhan F, Lian J, Wang B, et al. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer. Clin Sci. 2019;133:645\u201363. https:\/\/doi.org\/10.1042\/cs20180816.","journal-title":"Clin Sci"},{"key":"2152_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/bjc.2015.233","volume":"113","author":"SJ Thomas","year":"2015","unstructured":"Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK\/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer. 2015;113:365\u201371. https:\/\/doi.org\/10.1038\/bjc.2015.233.","journal-title":"Br J Cancer"},{"key":"2152_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, Bao Z, Lu J, Li L. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8:204. https:\/\/doi.org\/10.1038\/s41392-023-01468-7.","journal-title":"Signal Transduct Target Ther"},{"key":"2152_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/blood-2002-10-3149","volume":"102","author":"A Dimberg","year":"2003","unstructured":"Dimberg A, Karlberg I, Nilsson K, Oberg F. Ser727\/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0\/G1 arrest of U-937 cells. Blood. 2003;102:254\u201361. https:\/\/doi.org\/10.1182\/blood-2002-10-3149.","journal-title":"Blood"},{"key":"2152_CR28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/blood-2002-10-3149","volume":"102","author":"A Dimberg","year":"2003","unstructured":"Dimberg A, Karlberg I, Nilsson K, \u00d6berg F. Ser727\/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0\/G1 arrest of U-937 cells. Blood. 2003;102:254\u201361. https:\/\/doi.org\/10.1182\/blood-2002-10-3149.","journal-title":"Blood"},{"key":"2152_CR29","doi-asserted-by":"publisher","unstructured":"Olatoke T, Zhang EY, Wagner A, He Q, Li S, Astreinidis A, McCormack FX, Xu Y, Yu JJ. STAT1 Promotes PD-L1 Activation and Tumor Growth in Lymphangioleiomyomatosis. bioRxiv 2024, https:\/\/doi.org\/10.1101\/2024.12.11.627871","DOI":"10.1101\/2024.12.11.627871"},{"key":"2152_CR30","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1158\/0008-5472.Can-14-0847","volume":"74","author":"B Kharma","year":"2014","unstructured":"Kharma B, Baba T, Matsumura N, Kang HS, Hamanishi J, Murakami R, McConechy MM, Leung S, Yamaguchi K, Hosoe Y, et al. STAT1 drives tumor progression in serous papillary endometrial cancer. Cancer Res. 2014;74:6519\u201330. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-0847.","journal-title":"Cancer Res"},{"key":"2152_CR31","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1158\/0008-5472.Can-12-1347","volume":"72","author":"MA Zimmerman","year":"2012","unstructured":"Zimmerman MA, Rahman NT, Yang D, Lahat G, Lazar AJ, Pollock RE, Lev D, Liu K. Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. Cancer Res. 2012;72:4724\u201332. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-1347.","journal-title":"Cancer Res"},{"key":"2152_CR32","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1002\/ijc.32501","volume":"145","author":"X Zeng","year":"2019","unstructured":"Zeng X, Baba T, Hamanishi J, Matsumura N, Kharma B, Mise Y, Abiko K, Yamaguchi K, Horikawa N, Hunstman DG, et al. Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma. Int J Cancer. 2019;145:1635\u201347. https:\/\/doi.org\/10.1002\/ijc.32501.","journal-title":"Int J Cancer"},{"key":"2152_CR33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1101\/gad.479209","volume":"23","author":"OH Kr\u00e4mer","year":"2009","unstructured":"Kr\u00e4mer OH, Knauer SK, Greiner G, Jandt E, Reichardt S, G\u00fchrs KH, Stauber RH, B\u00f6hmer FD, Heinzel T. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev. 2009;23:223\u201335. https:\/\/doi.org\/10.1101\/gad.479209.","journal-title":"Genes Dev"},{"key":"2152_CR34","doi-asserted-by":"publisher","first-page":"102448","DOI":"10.1016\/j.xcrm.2025.102448","volume":"6","author":"PH Chiu","year":"2025","unstructured":"Chiu PH, Lai KC, Wang HL, Chang YW, Wu WC, Chen TH, Tsai YS, Song JH, Sun NY, Chau GY, et al. Therapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy. Cell Rep Med. 2025;6:102448. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102448.","journal-title":"Cell Rep Med"},{"key":"2152_CR35","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1158\/0008-5472.Can-10-4111","volume":"71","author":"EA Stronach","year":"2011","unstructured":"Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, Guney TG, Gourley C, Hennessy BT, Mills GB, et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res. 2011;71:4412\u201322. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-4111.","journal-title":"Cancer Res"},{"key":"2152_CR36","doi-asserted-by":"publisher","unstructured":"Sang H, Zhao X. JAK\/STAT Mediated Regulation of PD-L1 Expression in Breast Cancer: Molecular Mechanisms and Implications for Immunotherapy. iScience. 2026;114826. https:\/\/doi.org\/10.1016\/j.isci.2026.114826.","DOI":"10.1016\/j.isci.2026.114826"},{"key":"2152_CR37","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/15384047.2020.1824479","volume":"21","author":"F Liu","year":"2020","unstructured":"Liu F, Liu J, Zhang J, Shi J, Gui L, Xu G. Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer. Cancer Biol Ther. 2020;21:963\u201371. https:\/\/doi.org\/10.1080\/15384047.2020.1824479.","journal-title":"Cancer Biol Ther"},{"key":"2152_CR38","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s12967-025-06495-2","volume":"23","author":"M Hum","year":"2025","unstructured":"Hum M, Lee ASG. DNA methylation in breast cancer: early detection and biomarker discovery through current and emerging approaches. J Transl Med. 2025;23:465. https:\/\/doi.org\/10.1186\/s12967-025-06495-2.","journal-title":"J Transl Med"},{"key":"2152_CR39","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1200\/jco.2015.61.4578","volume":"33","author":"HI Hurwitz","year":"2015","unstructured":"Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM 3rd;, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, Randomized, et al. Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. J Clin Oncol. 2015;33:4039\u201347. https:\/\/doi.org\/10.1200\/jco.2015.61.4578.","journal-title":"J Clin Oncol"},{"key":"2152_CR40","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1200\/jco.23.02076","volume":"42","author":"CN Landen","year":"2024","unstructured":"Landen CN, Buckanovich RJ, Sill MW, Mannel RS, Walker JL, DiSilvestro PA, Mathews CA, Mutch DG, Hernandez ML, Martin LP, et al. Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study. J Clin Oncol. 2024;42:2537\u201345. https:\/\/doi.org\/10.1200\/jco.23.02076.","journal-title":"J Clin Oncol"},{"key":"2152_CR41","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1158\/1078-0432.Ccr-11-3225","volume":"18","author":"NN Khodarev","year":"2012","unstructured":"Khodarev NN, Roizman B, Weichselbaum RR. Molecular pathways: interferon\/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin Cancer Res. 2012;18:3015\u201321. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-3225.","journal-title":"Clin Cancer Res"},{"key":"2152_CR42","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13046-019-1153-8","volume":"38","author":"CK Looi","year":"2019","unstructured":"Looi CK, Chung FF, Leong CO, Wong SF, Rosli R, Mai CW. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. J Exp Clin Cancer Res. 2019;38:162. https:\/\/doi.org\/10.1186\/s13046-019-1153-8.","journal-title":"J Exp Clin Cancer Res"},{"key":"2152_CR43","doi-asserted-by":"publisher","unstructured":"Zemek RM, De Jong E, Chin WL, Schuster IS, Fear VS, Casey TH, Forbes C, Dart SJ, Leslie C, Zaitouny A, et al. Sensitization to immune checkpoint blockade through activation of a STAT1\/NK axis in the tumor microenvironment. Sci Transl Med. 2019;11. https:\/\/doi.org\/10.1126\/scitranslmed.aav7816.","DOI":"10.1126\/scitranslmed.aav7816"},{"key":"2152_CR44","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675\u20138. https:\/\/doi.org\/10.1038\/s41587-020-0546-8.","journal-title":"Nat Biotechnol"},{"key":"2152_CR45","doi-asserted-by":"publisher","first-page":"D512","DOI":"10.1093\/nar\/gku1267","volume":"43","author":"PV Hornbeck","year":"2014","unstructured":"Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 2014;43:D512\u201320. https:\/\/doi.org\/10.1093\/nar\/gku1267.","journal-title":"Nucleic Acids Res"},{"key":"2152_CR46","doi-asserted-by":"publisher","first-page":"D554","DOI":"10.1093\/nar\/gkae850","volume":"53","author":"X Huang","year":"2024","unstructured":"Huang X, Feng Z, Liu D, Gou Y, Chen M, Tang D, Han C, Peng J, Peng D, Xue Y. PTMD 2.0: an updated database of disease-associated post-translational modifications. Nucleic Acids Res. 2024;53:D554\u201363. https:\/\/doi.org\/10.1093\/nar\/gkae850.","journal-title":"Nucleic Acids Res"},{"key":"2152_CR47","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.gpb.2018.06.004","volume":"16","author":"H Xu","year":"2018","unstructured":"Xu H, Wang Y, Lin S, Deng W, Peng D, Cui Q, Xue YPTMD. A Database of Human Disease-Associated Post-Translational Modifications. Genom Proteom Bioinform. 2018;16:244\u201351. https:\/\/doi.org\/10.1016\/j.gpb.2018.06.004.","journal-title":"Genom Proteom Bioinform"},{"key":"2152_CR48","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284\u20137. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"Omics"},{"key":"2152_CR49","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48:W509\u201314. https:\/\/doi.org\/10.1093\/nar\/gkaa407.","journal-title":"Nucleic Acids Res"},{"key":"2152_CR50","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2012","unstructured":"Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2012;41:D955\u201361. https:\/\/doi.org\/10.1093\/nar\/gks1111.","journal-title":"Nucleic Acids Res"},{"key":"2152_CR51","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","volume":"154","author":"A Basu","year":"2013","unstructured":"Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, Ebright RY, Stewart ML, Ito D, Wang S, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154:1151\u201361. https:\/\/doi.org\/10.1016\/j.cell.2013.08.003.","journal-title":"Cell"},{"key":"2152_CR52","doi-asserted-by":"publisher","unstructured":"Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3(Article3). https:\/\/doi.org\/10.2202\/1544-6115.1027.","DOI":"10.2202\/1544-6115.1027"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02152-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02152-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02152-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T01:12:05Z","timestamp":1783559525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02152-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2152"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02152-0","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"261"}}